Introduction............................................................................................................ 3
What is changing?.................................................................................................. 4
When do these changes take effect?................................................................... 5
Who will be affected?............................................................................................ 5
Why is coverage changing?.................................................................................. 5
How can I identify which of my patients will be affected?.............................. 7
Will patients need new Special Authority approval?....................................... 6
Are Special Authority criteria changing?............................................................ 6
What is the Biosimilar Patient Support Fee?...................................................... 7
What do I need to do to switch patients?............................................................. 7
What about patients who cannot switch to a biosimilar?............................... 7
What patient support programs are available for biosimilars?......................... 8
Will patient access to infusion centres change?............................................... 9
How can I support patients with questions and concerns?.............................. 10
What is the nocebo effect and how can I help prevent it?................................. 11
What evidence supports biosimilar adoption and switch?............................... 11
Will this be the only biosimilar switch?.............................................................. 12
Where can I find more resources for my patients?............................................. 13
What if I have questions or need more information?....................................... 13

Biosimilar Basics: A Primer for Patient Discussions
What is a biologic drug?....................................................................................... 14
What is a biosimilar drug?.................................................................................. 14
How is a biosimilar proven to be safe and effective?....................................... 15
Are biosimilars interchangeable with their biologic originator?....................... 15
What are the benefits of biosimilars?................................................................. 15
What are the officials saying about biosimilars?............................................... 16

Across Canada, biologic drugs are a major contributor to healthcare costs increasing at an unsustainable rate. In 2017, Canada spent over $1.1 billion on Remicade® alone—more than on any other drug. With new drugs frequently entering the market (including new biologics and innovative therapies), the cost pressures for Canada’s drug plans will only continue to increase.

One solution to this challenge is already available: biosimilar versions of originator biologic drugs offer significant cost savings. In B.C., etanercept biosimilars offer a 28% reduction in cost compared to Enbrel® and a 50% reduction in cost for infliximab biosimilars compared to Remicade.

Despite these price differences, biosimilars have not yet captured much market share in Canada. At the end of 2017, etanercept biosimilars (approved in Canada since August 2016) account for only 3.1% of etanercept use. Infliximab biosimilars (approved in Canada since January 2014) account for only 4% of infliximab use.

Biosimilar uptake has been limited by many factors, including misconceptions about the safety and efficacy of biosimilars and reluctance to change the status quo.

B.C.’s previous strategy to encourage biosimilar uptake by listing those brands preferentially for treatment-naïve patients has been well-received; however, the impact of this strategy is limited by the small proportion of new starts.

With an ever-growing body of evidence and the support of stakeholders, PharmaCare is now positioned to enable the expansion of treatment options and the improvement of patient access by introducing the Biosimilars Initiative.

The Biosimilars Initiative changes coverage for specific biologic drugs. Patients and their prescribers have a period of 6 months to discuss switching from an originator brand to a biosimilar brand. Coverage and Special Authority (SA) approval is provided for both originator and biosimilar brands during the switch. Patients unable to switch or who have an adverse response to the biosimilar(s) can seek exceptional SA coverage for the originator.

PharmaCare’s strategy to ensure a successful switch includes:
- Involving various practitioners in patient identification, education and support
- Providing time to identify affected patients and guide them through the switch process
- Ensuring patient supports are in place for continuous care
- Having options for those unable to switch or experience challenges with switching
- Identifying areas of concern and providing information for both patients and practitioners
- Providing call-in information sessions and responsive contacts for healthcare practitioners
- Monitoring drug utilization, patient outcomes, and stakeholder feedback

The role of the prescriber in the switch process is paramount. A prescriber sets the tone of the switch discussion, serving as the primary and most trusted information source, facilitates continuity of care, and empowers the patient to expect and realize the best outcomes.

In accordance with Health Canada recommendations, the decision to switch to a biosimilar should be made by a well-informed patient and their prescriber. PharmaCare has created this guide to provide information to support your discussions with affected patients.

(National statistics referenced in the section above are found in the Patented Medicine Prices Review Board Meds Entry Watch 2017 report.)
PharmaCare is changing coverage of certain biological drugs, including etanercept and infliximab.

Coverage for the original biologic (originator) drugs will be discontinued for affected patients, and coverage will instead be provided for their biosimilars:

**PHASE 1: May 27 to November 25, 2019**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Originator</th>
<th>Biosimilars</th>
<th>Indications Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>etanercept</td>
<td>Enbrel®</td>
<td>Brenzys®</td>
<td>Ankylosing Spondylitis, Rheumatoid Arthritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Erelzi™</td>
<td>Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis</td>
</tr>
<tr>
<td>infliximab</td>
<td>Remicade®</td>
<td>Inflectra®</td>
<td>Ankylosing Spondylitis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renflexis®</td>
<td></td>
</tr>
<tr>
<td>insulin glargine</td>
<td>Lantus®</td>
<td>Basaglar™</td>
<td>Diabetes (Type 1 and 2)</td>
</tr>
</tbody>
</table>

For affected patients with existing Special Authority (SA) approval for etanercept or infliximab to maintain their coverage, prescribers must write a new prescription, indicating the switch to a biosimilar option. The patient’s existing SA remains in effect until the next renewal date (if applicable).

New SA requests and renewals for etanercept and infliximab will be granted for biosimilar brands only.

At this time, coverage of insulin glargine is also changing to biosimilar Basaglar™, and coverage of Lantus® will be discontinued. If your patients may be affected by this change in addition to their infliximab or etanercept, please encourage them to speak with their endocrinologist, general practitioner, nurse practitioner, or Diabetes Education Centre.

In Phase 2 of the Biosimilars Initiative, PharmaCare will change coverage for patients taking Remicade for Crohn’s disease or ulcerative colitis. The switching of Remicade patients has been designed in two phases to allow for stakeholder engagement and ensure that switch support resources have capacity to address patient and prescriber needs.

**PHASE 2: Summer 2019 to early 2020 (Dates to be confirmed)**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Originator</th>
<th>Biosimilars</th>
<th>Indications Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>infliximab</td>
<td>Remicade®</td>
<td>Inflectra®</td>
<td>Crohn’s Disease, Ulcerative Colitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renflexis®</td>
<td></td>
</tr>
</tbody>
</table>

To enable expansion of the PharmaCare formulary and B.C. health services, PharmaCare develops evidence-informed strategies to better optimize how our public resources are used. Biologic drugs represent a huge portion of the annual PharmaCare budget, and biosimilars represent a correspondingly large, but unrealized, opportunity to find value that can be applied to new treatments and services.

In B.C., the biologic drugs being switched (Lantus, Enbrel, and Remicade) represent some of the largest provincial drug expenditures. In 2018, PharmaCare spent $125 million on just these three originator drugs.

Despite being listed preferentially for new starts, the biosimilars for these drugs have captured only a fraction of the market: Basaglar represented only 1.7% of 2018 insulin glargine PharmaCare expenditures, Brenzys and Erelzi only 6.8%, and Inflectra and Renflexis only 5.9%.

PharmaCare is always reviewing new drugs, new indications, and existing coverage and criteria; the provincial formulary must evolve and adapt to the current market, clinical requirements, best practices, and the needs of B.C. residents and practitioners.
What do I need to do to switch patients?

To switch your patients to a biosimilar:

1. Identify an affected patient.
2. Discuss switching to a biosimilar with the patient.
3. Write your patient a new prescription, clearly indicating the discontinuation of the originator and start of the biosimilar brand chosen.
4. Initiate enrolment in the patient support program for the biosimilar (if applicable).
5. Submit the Biosimilar Patient Support Fee with your MSP billing.
6. For any patients unable to switch, submit a new SA request for exceptional coverage of Remicade or Enbrel.

What is the Biosimilars Patient Support Fee?

The Biosimilar Patient Support Fee is a $50 fee billable to MSP in addition to other services billed on the same date of service, using the Teleplan claims system. They are being offered in recognition of the additional effort involved in contacting patients and supporting their switch to a biosimilar. This fee can be claimed once per affected patient during the transition period, regardless of whether that patient switches to a biosimilar.

- Biosimilar Patient Support Fee: Enbrel to Biosimilar Etanercept
  Fee code: 97010
  Effective: May 27–November 25, 2019
  Limited to: Rheumatologists, Internal Medicine Specialists
- Biosimilar Patient Support Fee: Remicade to Biosimilar Infliximab
  Fee code: 97009
  Effective: May 27–November 25, 2019
  Limited to: Rheumatologists, Dermatologists, Internal Medicine Specialists

What about patients who cannot switch to a biosimilar?

For patients with a clinical requirement that prevents switching, you can request exceptional coverage of Enbrel or Remicade by submitting a new SA request (HLTH 5354 for rheumatoid arthritis, HLTH 5366 for ankylosing spondylitis, HLTH 5361 for psoriatic arthritis) and clearly identifying why the patient is unable to switch.

Exceptional requests will be reviewed by Special Authority on a case-by-case basis. After an initial review by SA pharmacists, any requests requiring additional input will be submitted to the Drug Benefit and Adjudication Advisory Committee for review by a panel of three rheumatologists.

Exceptional requests should be submitted as soon as possible to allow for review, follow-up inquiries, and to ensure uninterrupted coverage.

Will patients need new Special Authority approval?

Patients with existing SA for etanercept or infliximab do not require a new SA for the biosimilar version of their medication. The existing SA remains in effect until the next scheduled renewal date (if applicable).

If a patient's SA expires during the switch period, it will be renewed for biosimilars only.

Note that patients are expected to trial a biosimilar. If a trial has been attempted and halted, the rationale for halting the trial must be well documented in the request for exceptional coverage, and be unlikely to recur or intensify if the patient resumes taking the originator.

Patients with a clinical requirement that prevents switching can have their prescriber submit a new SA request for exceptional coverage of the originator biologic. Exceptional requests will be reviewed by Special Authority on a case-by-case basis.

Are Special Authority criteria for infliximab and etanercept changing?

- Disease-Modifying Antirheumatic Drugs (DMARDs) for Rheumatoid Arthritis
  The criteria for initial coverage of a targeted DMARD have been reduced to require a trial of subcutaneous methotrexate plus a trial of just one other conventional synthetic DMARD. A trial with an adequate combination of csDMARDs is still required.
  More details are available on the HLTH 5345 form.
- DMARDs for Ankylosing Spondylitis
  The NSAID-related criteria for initial coverage of a targeted DMARD have been reduced to include two-week trials of at least two different NSAIDs.
  More details are available on the HLTH 5365 form.
- DMARDs for Psoriatic Arthritis
  The NSAID-related criteria for initial coverage of a targeted DMARD have been reduced to include trials of at least two weeks with two different NSAIDs.
  More details are available on the HLTH 5360 form.

How can I identify which of my patients will be affected?

To assist in identifying which of your patients you may need to speak with about biosimilar switching, we can send you a list of PharmaCare-covered patients who have filled a prescription for Remicade or Enbrel, written by you, in the past 6 months.

Please complete and submit the enclosed HLTH 5841 Patient List Request form. Within two weeks, we will send you a list of the names of patients who may be affected by biosimilar switching.
What patient support programs are available for biosimilars?

Biosimilar manufacturers are committed to minimizing the impact of this initiative for both patients and prescribers, especially regarding patient support program processes and services, as well as access to infusion centres. For more information, support, and enrollment forms and assistance, contact the patient support programs below.

INFLECTRA
The Inflectra Patient Assistance Program provides support services, including coordination with private payers and infusion centres, for patients taking Inflectra. After you submit the enrollment form on behalf of your patient, they will be contacted by an Inflectra Navigator.

- **B.C. Inflectra Navigators**
  - Marlena Giordano: District Manager, B.C. and Ontario
  - Kelly Blumeschein: Inflectra Navigator, Kelowna and Kamloops
  - Rekha Singh: Inflectra Navigator, Vancouver and Lower Mainland
  - Jennifer Bayntun: Inflectra Navigator, Vancouver
  - Jennifer Paronen: Inflectra Navigator, Vancouver Island

- **B.C. Inflectra coordinators**
  - Meghan Keenan: Meghan.keenan@merckharmony.ca, 1-289-295-0702
  - Beth-Anne Holbrook: bethanne.holbrook@merckharmony.ca, 1-289-295-0711
  - Kirk Chen: kirk.chen@merckharmony.ca, 1-289-295-0710
  - Bobbie Uppal: bobbie.uppal@merckharmony.ca, 1-289-295-0709
  - Rose Wilbee, 1-604-999-1164
  - Meghan Keenan: Meghan.keenan@merckharmony.ca, 1-289-295-0702

- **For additional information, contact the B.C. Patient Support Program Managers:**
  - Rose Wilbee, 1-604-999-1164
  - Baloo Dosanjh, 1-604-999-1173

RENFLEXIS AND BRENZYS
The Merck Harmony® Patient Support Program provides support services, including coordination with private payers (for patients taking Renflexis or Brenzys) and infusion centres, for patients taking Renflexis. To enroll in the program, both prescriber and patient must sign a completed enrollment form.

- **B.C. Renflexis Navigators**
  - Rekha Singh: Inflectra Navigator, Vancouver and Lower Mainland
  - Jennifer Paronen: Inflectra Navigator, Vancouver Island
  - Rekha Singh: Inflectra Navigator, Vancouver and Lower Mainland

- **B.C. Renflexis coordinators**
  - Karen Fisher: kfisher@innomar-strategies.com, 1-604-238-1425
  - Jie Man: jie.man@innomar-strategies.com, 1-604-347-8815

- **For additional information, contact the B.C. Patient Support Program Managers:**
  - Karen Fisher: kfisher@innomar-strategies.com, 1-604-238-1425
  - Jie Man: jie.man@innomar-strategies.com, 1-604-347-8815

ERELZI
The Erelzi XPOSE® program provides support services, including self-injection training, for patients taking Erelzi. To enroll in the program, both prescriber and patient must sign a completed enrollment form.

- **B.C. Erelzi Navigators**
  - Marlena Giordano: District Manager, B.C. and Ontario
  - Jennifer Paronen: Inflectra Navigator, Vancouver Island

- **B.C. Erelzi coordinators**
  - Bobbie Uppal: bobbie.uppal@merckharmony.ca, 1-289-295-0709
  - Rose Wilbee, 1-604-999-1164

Will patient access to infusion centres change?
Patients receiving their Remicade infusions at a BioAdvance clinic will move to a new infusion centre as part of their biosimilar switch. The patient support program will coordinate this change. Infusion centres are available across the province:

### INFLECTRA
<table>
<thead>
<tr>
<th>City</th>
<th>Clinic</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbotsford</td>
<td>InnomarClinics™ Abbotsford</td>
<td>2168 McCallum Road, Unit 2</td>
</tr>
<tr>
<td>Burnaby</td>
<td>InnomarClinics™ Burnaby</td>
<td>7885 6 Street, Suite 208</td>
</tr>
<tr>
<td>Chilliwack</td>
<td>InnomarClinics™ Chilliwack</td>
<td>45800 Promontory Road, Suite 203</td>
</tr>
<tr>
<td>Courtenay</td>
<td>InnomarClinics™ Courtenay</td>
<td>1350 England Avenue, Suite 101</td>
</tr>
<tr>
<td>Cranbrook</td>
<td>InnomarClinics™ Cranbrook</td>
<td>4411 Avenue S, Cranbrook</td>
</tr>
<tr>
<td>Delta</td>
<td>InnomarClinics™ Delta-Surrey</td>
<td>6345 120 Street, Suite 115</td>
</tr>
<tr>
<td>Kamloops</td>
<td>InnomarClinics™ Kamloops</td>
<td>546 St. Paul Street, Suite 160</td>
</tr>
<tr>
<td>Kelowna</td>
<td>InnomarClinics™ Kelowna</td>
<td>3001 Tutt Street, Suite 303</td>
</tr>
<tr>
<td>Nainaimo</td>
<td>InnomarClinics™ Nainaimo</td>
<td>1450 Waddington Road, Suite 202</td>
</tr>
<tr>
<td>North Vancouver</td>
<td>InnomarClinics™ North Vancouver</td>
<td>145 15 Street W, Suite 101</td>
</tr>
<tr>
<td>Penticton</td>
<td>InnomarClinics™ Penticton</td>
<td>1436 Balfour Street</td>
</tr>
<tr>
<td>Penticton Infusion Clinic</td>
<td>InnomarClinics™ Penticton Infusion Clinic</td>
<td>527 Carni Avenue</td>
</tr>
<tr>
<td>Prince George</td>
<td>InnomarClinics™ Prince George</td>
<td>1811 Victoria Street, Suite 306</td>
</tr>
<tr>
<td>Richmond</td>
<td>InnomarClinics™ Richmond</td>
<td>6091 Gilbert Road, Suite 440</td>
</tr>
<tr>
<td>Vancouver</td>
<td>Artus Health Centre</td>
<td>839 West Broadway</td>
</tr>
<tr>
<td>Vancouver</td>
<td>InnomarClinics™ Vancouver-Fairmont</td>
<td>750 West Broadway Avenue, Suite 1406</td>
</tr>
<tr>
<td>Vancouver</td>
<td>Pacific Gastroenterology Associates</td>
<td>1190 Homby St., Suite 770</td>
</tr>
<tr>
<td>Vancouver</td>
<td>Mary Pack Arthritis Clinic</td>
<td>3655 West 10 Avenue</td>
</tr>
<tr>
<td>Vernon</td>
<td>InnomarClinics™ Vernon</td>
<td>3210 25 Avenue, Suite 304</td>
</tr>
<tr>
<td>Victoria</td>
<td>InnomarClinics™ Victoria</td>
<td>1350 Cedar Hill Cross Road, Suite 330</td>
</tr>
<tr>
<td>West Vancouver</td>
<td>InnomarClinics™ West Vancouver</td>
<td>420 17 Street, Suite 202</td>
</tr>
</tbody>
</table>

### RENFLEXIS
<table>
<thead>
<tr>
<th>City</th>
<th>Clinic</th>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbotsford</td>
<td>Bayshore Abbotsford ICN</td>
<td>2151 McCallum Road, Suite 401</td>
</tr>
<tr>
<td>Chilliwack</td>
<td>Bayshore Chilliwack ICN</td>
<td>9181 Main Street, Suite 101</td>
</tr>
<tr>
<td>Courtenay</td>
<td>Bayshore partner Courtenay (ICN)</td>
<td>1350 England Avenue, Suite 104</td>
</tr>
<tr>
<td>Kelowna</td>
<td>Bayshore Kelowna ICN</td>
<td>3001 Tutt Street, Suite 210</td>
</tr>
<tr>
<td>Nanaimo</td>
<td>Bayshore Nanaimo ICN</td>
<td>1630 Terminal Ave N, Suite 204</td>
</tr>
<tr>
<td>New Westminster</td>
<td>Bayshore New Westminster ICN</td>
<td>301 Columbia Street E, Suite 104</td>
</tr>
<tr>
<td>North Vancouver</td>
<td>Bayshore North Vancouver ICN</td>
<td>168 13th Street East, Suite 210</td>
</tr>
<tr>
<td>Penticton</td>
<td>Penticton Infusion Clinic</td>
<td>527 Carni Ave</td>
</tr>
<tr>
<td>Richmond</td>
<td>Bayshore Richmond ICN</td>
<td>6051 Gilbert Road, Suite 301</td>
</tr>
<tr>
<td>Sidney</td>
<td>Bayshore Sidney ICN</td>
<td>9840 Fifth Street, Suite 102</td>
</tr>
<tr>
<td>Surrey</td>
<td>Bayshore Surrey ICN</td>
<td>13710 94A Avenue, Suite 307</td>
</tr>
<tr>
<td>Vancouver</td>
<td>Artus Health Centre</td>
<td>839 West Broadway</td>
</tr>
<tr>
<td>Vancouver</td>
<td>Bayshore Vancouver ICN</td>
<td>555 West 12 Avenue, Suite 410</td>
</tr>
<tr>
<td>Vernon</td>
<td>Bayshore Vernon ICN</td>
<td>2306 Hwy 6, Suite 225</td>
</tr>
<tr>
<td>Victoria</td>
<td>Bayshore Victoria ICN</td>
<td>1900 Richmond Road, Suite 380</td>
</tr>
<tr>
<td>Victoria</td>
<td>Bayshore partner Langford (ICN)</td>
<td>2349 Millstream Road, Suite 105</td>
</tr>
<tr>
<td>Victoria</td>
<td>Bayshore partner Victoria (ICN)</td>
<td>1120 Yates Street, Suite 305</td>
</tr>
</tbody>
</table>
How can I support patients with questions and concerns?

Patient acceptance of biosimilars is, understandably, easier to achieve among treatment-naïve patients started on a biosimilar. Treatment-experienced, stable patients using an originator biologic may require more support.

The best response to any concern your patient may have is your expertise and experience as a healthcare practitioner, as well as the provision of additional information. Patients who feel they understand the change and why it’s necessary, who trust their practitioners, and who understand that there is a support plan in place are more positive and achieve better outcomes.

PharmaCare has created a brief patient information sheet for you to provide to patients to summarize the change and direct them to more detailed resources available at www.gov.bc.ca/biosimilars. Included later in this guide is a biosimilars primer that may be useful in explaining biosimilars to your patients.

The most critical information usually required by patients is that biosimilars:

• are safe and effective
• will work like their current medication
• have no additional risk of adverse reactions or immunological response
• do not require significant changes to their routines or dosing
• are accompanied by patient support programs that will help them with benefits coordination, scheduling, access, etc.
• are available at infusion centres near them (though it may be a different infusion centre than they currently attend)
• are well-understood, that switching from an originator has been extensively studied, and that switch programs have been successful around the world

As an additional resource, Arthritis Consumer Experts have created a Patient Conversation Guide for prescribers to assist in preparing for switch discussions. This guide and other resources for you and your patients are available at www.gov.bc.ca/biosimilars/prescribers.

It is important to recognize this is a switch process (not a substitution policy), where patient and practitioner education, collaborative decision making, and exception options for those who need them are key. Practitioners are essential in empowering patients with information, demonstrating that there is a support plan in place and setting people up for success.

What is the nocebo effect and how can I help prevent it?

The greatest hurdle for successful switch to a biosimilar is the potential for the nocebo effect, where a patient’s negative expectations both psychologically and physiologically affect the outcomes of and adherence to their treatment.

Patients’ pre-existing beliefs, previous healthcare experiences, and mindset can have a very real effect on symptoms and their sense of wellbeing.

Many factors contribute to a patient’s likelihood of experiencing the nocebo effect:

• Patient factors, such as other mental health comorbidities (especially anxiety, depression, or cognitive impairment), language barriers, a history of negative interactions with the healthcare system, or the use of online media as a source of medical information (where negative responses are highly over-represented, and bias or misrepresentation go unchecked).
• Practitioner factors, such as language choices, manner, non-verbal communication, or unbalanced focus on potential adverse reactions.
• Health care setting factors, such as the physical environment, comfort, ease of access, and interactions with other staff and patients.
• Drug factors, such as an appearance or smell, administration route or routine, change in delivery device, labelling, and price.

A variety of strategies can be effective in preventing the nocebo effect:

• Empower people with information and an active role in the switch process.
• Be attentive and empathetic, so patients feel safe asking questions or expressing concerns.
• Balance the presentation of desired effects and adverse effects.
• Promote a neutral or positive outlook instead of reiterating fears.
• Acknowledge the nocebo effect itself.
• Speak face-to-face, when possible.
• Discuss a plan for follow-up, acknowledging that there are options, no matter the outcome.

In international studies, the nocebo effect was of particular note in the treatment of rheumatoid arthritis, where patient-reported outcomes were central to assessing response to a drug and fewer objective clinical measures exist.

What evidence supports biosimilar adoption and switching?

The safety, efficacy, immunogenicity, and therapeutic similarity of biosimilars is evidenced by a large body of clinical evidence, extensive post-market pharmacovigilance, as well as the results of switch programs in other jurisdictions.

Additional reading and study summaries are available online at www.gov.bc.ca/biosimilars/prescribers.

The Ministry will be carefully monitoring drug utilization, patient outcomes, and the response from patients and healthcare practitioners during and after biosimilar switching in B.C.
Will this be the only biosimilar switch?

In Phase 1 of the Biosimilars Initiative, the focus is on switching all Lantus users, patients using Remicade for rheumatological or dermatological indications, and those using Enbrel for rheumatological indications.

Phase 2 of the Biosimilars Initiative will focus on switching patients using Remicade for GI indications.

It is likely that further switches to biosimilars will occur for other indications and drugs. All switches will be planned in consultation with the affected prescribers and stakeholders.

“Policies and position statements on biosimilars are evolving to reflect increasing experience with and confidence in biosimilars as a treatment option.”

Health Canada's 2017 Biosimilars Workshop: Summary Report

Where can I find more resources for my patients?

A library of patient resources is available online at www.gov.bc.ca/biosimilars. Here they can find detailed information about:

- the Biosimilars Initiative
- how they may be affected
- biologic and biosimilar drugs
- answers to frequently asked questions
- other resources and reading (including materials developed by patient groups)

If you require additional printed patient information sheets, please contact us at Biosimilars.Initiative@gov.bc.ca.

What if I have questions or need more information?

PharmaCare is committed to supporting and working with healthcare practitioners throughout the Biosimilars Initiative.

Additional information is available at www.gov.bc.ca/biosimilars/prescribers.

Call-in information sessions, hosted by members of the PharmaCare team and specialist guests, will be scheduled throughout the transition period. An up-to-date schedule of information sessions will be available at the link above.

The PharmaCare team is also available at Biosimilars.Initiative@gov.bc.ca for your questions and feedback.
BIOSIMILAR BASICS

What is a biologic drug?
Most drugs (like aspirin, metformin, antibiotics, etc.) are considered synthetic drugs, where certain chemicals can be combined in a lab using a set recipe. The result is a consistent drug product composed of relatively small molecules that can be easily tested to ensure everything is identical in composition and potency across different batches and different manufacturers.

Biologic drugs were first introduced in the 1980s, as advancements allowed scientists to manipulate other organisms’ cells and better identify complex compounds and feedback systems involved in human metabolism and disease processes.

Biologic drugs are produced by engineering a living cell line (like bacteria, yeast, or mammal cells, etc.) to produce a specific protein compound that is then collected and purified for human use. These protein compounds are very large and complex compared to synthetic drugs.

Biologic drugs have created new fields of research and disease treatment, providing more and better options for cancer treatment and the management of chronic diseases like rheumatoid arthritis, Crohn’s disease, and diabetes.

What is a biosimilar drug?
Like with synthetic drugs, when a unique biologic drug is no longer protected by patents, other manufacturers can begin to produce the protein compound under a different brand name. These new versions of a biologic drug are called biosimilars.

Biosimilars are designed to be highly similar to the biologic originator and have no difference in effect. Because biologics are so complex, both to manufacture and in structure, it is not possible to demonstrate that a biologic originator and its biosimilar are perfectly identical. (Nor is it possible to demonstrate that a batch of any biologic—originator or biosimilar—is identical to its previous batches).

Producing biosimilars builds on the work already done for the biologic originator, and therefore requires less investment into research and development. This means the biosimilar product can be offered at a lower cost, providing patients and the healthcare system better value for the same benefit.

A PRIMER FOR PATIENT DISCUSSIONS

How is a biosimilar drug proven to be as safe and effective as the originator?
Health Canada’s rigorous requirements demand that a biosimilar demonstrate that there are no clinically meaningful differences in terms of physiochemical structure, quality, potency, pharmacokinetics, and immunogenicity. Clinical efficacy studies must demonstrate that the therapeutic effects of the biosimilar (both risk and benefit) are consistent.

After a drug is approved for sale, post-market analyses and studies can further demonstrate no meaningful differences in clinical efficacy between a biosimilar and the originator. These studies are common in the European Union, where biosimilars have been in use longer and have a higher adoption rate.

Are biosimilars interchangeable with their biologic originator?
As biosimilars cannot be proven to be identical to their biologic originator, they are not classified as interchangeable; that is, a pharmacist could not substitute one for the other at the pharmacy level without involvement of the prescribing physician.

Biosimilars and their originator biologics are proven to have no clinically meaningful differences in function or effect, meaning that switching from one to another is appropriate at the direction of the prescribing physician, in collaboration with the patient.

What are the benefits of biosimilars?
Biosimilars offer major cost savings to the healthcare system, which allows for improved access to drug therapies for more people who need them. Biosimilars also contribute to a healthy and competitive drug market in Canada, supporting diversification of drug products and manufacturers, as well as driving both demand and capacity for newer, better drugs.

“Health Canada’s rigorous standards for authorization mean that patients and health care providers can have the same confidence in the quality, safety and efficacy of a biosimilar as any other biologic drug.”

Health Canada Fact Sheet: Biosimilars 2017

“Health Canada considers a well-controlled switch from a reference biologic drug to a biosimilar in an approved indication to be acceptable, and recommends that a decision to switch a patient being treated with a reference biologic drug to a biosimilar, or between any biologics, be made by the treating physician in consultation with the patient and take into account any policies of the relevant jurisdiction.”

Health Canada’s 2017 Biosimilars Workshop: Summary Report
WHAT OFFICIALS ARE SAYING ABOUT BIOSIMILARS

“Policies and position statements on biosimilars are evolving to reflect increasing experience with and confidence in biosimilars as a treatment option.”

Health Canada’s 2017 Biosimilars Workshop: Summary Report

“By increasing treatment options, biosimilars can enhance competition in the market for biological products without reducing incentives to innovate.”

U.S. Food and Drug Administration
Biosimilars Action Plan: Balancing Innovation and Competition
July 2018

“Policies regarding switching from a reference biologic drug to a biosimilar should consider the need for cost savings as well as patient and physician choice.”

Health Canada’s 2017 Biosimilars Workshop: Summary Report

“Patients and their physicians can expect that there will be no clinically meaningful differences between taking a reference product and a biosimilar when these products are used as intended.”

U.S. Food and Drug Administration
Prescribing Biosimilar Products
2019

“In Europe, the availability of lower priced biosimilars has been reported to reduce the average list prices of reference products as well as prices of products within the whole therapeutic class.”

Canadian Agency for Drugs and Technology in Health
Biosimilars—Regulatory, Health Technology Assessment, Reimbursement Trends, and Market Outlook
January 2018

“Over the past 10 years, the EU has approved the highest number of biosimilars worldwide, amassing considerable experience in their use and safety. The evidence acquired over 10 years of clinical experience shows that biosimilars approved through EMA can be used safely and effectively in all their approved indications as other biological medicines. Over the last 10 years, the EU monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicines.”

European Medicines Agency
Biosimilars in the EU: Information Guide for Healthcare Professionals
2017
BIOSIMILARS INITIATIVE

www.gov.bc.ca/biosimilars/prescribers

Biosimilars.Initiative@gov.bc.ca

BRITISH COLUMBIA Ministry of Health